Erik Manting
Chief Executive Officer at MENDUS AB
Net worth: 58 933 $ as of 2024-04-29
Erik Manting active positions
| Companies | Position | Start | End |
|---|---|---|---|
| MENDUS AB | Chief Executive Officer | 2021-03-15 | - |
| Corporate Officer/Principal | - | 2021-03-15 | |
| TRANSCODE THERAPEUTICS, INC. | Director/Board Member | 2020-12-19 | - |
| Independent Dir/Board Member | 2020-12-19 | - | |
Synerkine Pharma BV
 Synerkine Pharma BV Miscellaneous Commercial ServicesCommercial Services Synerkine Pharma BV focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. The company was founded by Hans Preusting in 2018 and is headquartered in Utrecht, Netherlands. | Director/Board Member | 2019-02-28 | - |
Career history of Erik Manting
Former positions of Erik Manting
| Companies | Position | Start | End |
|---|---|---|---|
DCPrime BV
 DCPrime BV Pharmaceuticals: MajorHealth Technology DCPrime BV engages in the provision of therapeutic vaccines for the treatment of cancer. It develops whole-cell-based vaccine addressing blood cancers with a high risk of relapse. The company was founded by Ada M. Kruisbeek and Rik J. Scheper in March 2005 and is headquartered in Leiden, the Netherlands. | Chief Executive Officer | 2016-12-31 | 2020-11-30 |
Kempen & Co. NV
 Kempen & Co. NV Financial ConglomeratesFinance Kempen & Co. NV provides financial services to professional investors. The company's clients include institutional investors, companies, financial institutions, public & semi-public institutions, foundations and high-net-worth private clients. The company was founded in July 1903 by A. J. Kempen and M. D. de Lange and is headquartered in Amsterdam, The Netherlands. | Corporate Officer/Principal | 2012-09-30 | 2017-08-31 |
| Rabo Securities NV | Analyst-Equity | 2005-09-13 | 2005-09-13 |
| Bioentrepreneur BV | Founder | 2017-08-31 | - |
Statistics
International
| Netherlands | 6 |
| Sweden | 2 |
| United States | 2 |
Operational
| Chief Executive Officer | 2 |
| Corporate Officer/Principal | 2 |
| Director/Board Member | 2 |
Sectoral
| Health Technology | 4 |
| Finance | 3 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| MENDUS AB | Health Technology |
| TRANSCODE THERAPEUTICS, INC. | Health Technology |
| Private companies | 5 |
|---|---|
| Rabo Securities NV | Finance |
DCPrime BV
DCPrime BV Pharmaceuticals: MajorHealth Technology DCPrime BV engages in the provision of therapeutic vaccines for the treatment of cancer. It develops whole-cell-based vaccine addressing blood cancers with a high risk of relapse. The company was founded by Ada M. Kruisbeek and Rik J. Scheper in March 2005 and is headquartered in Leiden, the Netherlands. | Health Technology |
Synerkine Pharma BV
Synerkine Pharma BV Miscellaneous Commercial ServicesCommercial Services Synerkine Pharma BV focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. The company was founded by Hans Preusting in 2018 and is headquartered in Utrecht, Netherlands. | Commercial Services |
| Bioentrepreneur BV | |
Kempen & Co. NV
Kempen & Co. NV Financial ConglomeratesFinance Kempen & Co. NV provides financial services to professional investors. The company's clients include institutional investors, companies, financial institutions, public & semi-public institutions, foundations and high-net-worth private clients. The company was founded in July 1903 by A. J. Kempen and M. D. de Lange and is headquartered in Amsterdam, The Netherlands. | Finance |
- Stock Market
- Insiders
- Erik Manting
- Experience
